Frontline Genomics talks to Ranga Sarangarajan about our AI guided GBM trials


March 10, 2017

BERG’s Chief Scientific Officer, Ranga Sarangarajan talks to Liz Harley at Frontline Genomics about our Phase I/II glioblastoma multiforme trials that are being guided by BERG’s AI platform. Full article can be viewed here: http://www.frontlinegenomics.com/opinion/10472/artificial-intelligence-drug-cancer-berg/

Recent news